Your browser doesn't support javascript.
loading
Symptom management care pathway adaptation process and specific adaptation decisions.
Vettese, Emily; Sherani, Farha; King, Allison A; Yu, Lolie; Aftandilian, Catherine; Baggott, Christina; Agarwal, Vibhuti; Nagasubramanian, Ramamoorthy; Kelly, Kara M; Freyer, David R; Orgel, Etan; Bradfield, Scott M; Kyono, Wade; Roth, Michael; Klesges, Lisa M; Beauchemin, Melissa; Grimes, Allison; Tomlinson, George; Dupuis, L Lee; Sung, Lillian.
Afiliação
  • Vettese E; Program in Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, 686 Bay Street, Toronto, ON, M5G 0A4, Canada.
  • Sherani F; Driscoll Children's Hospital, Cancer and Blood Disorders Center, 3533 S. Alameda Street, Corpus Christi, TX, 78411, US.
  • King AA; Texas A&M University, College Station, TX, US.
  • Yu L; Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO, 63110, US.
  • Aftandilian C; Louisiana State University Health Sciences Center/Children's Hospital, 200 Henry Clay Avenue, New Orleans, LA, 70118, USA.
  • Baggott C; Stanford University, 800 Welch Road, Palo Alto, CA, 94304, US.
  • Agarwal V; Stanford University, 800 Welch Road, Palo Alto, CA, 94304, US.
  • Nagasubramanian R; Nemours Children's Hospital of The Nemours Foundation, 6535 Nemours Parkway, Orlando, FL, 32827, US.
  • Kelly KM; Nemours Children's Hospital of The Nemours Foundation, 6535 Nemours Parkway, Orlando, FL, 32827, US.
  • Freyer DR; Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, 665 Elm St., Buffalo, NY, 14203, US.
  • Orgel E; Cancer and Blood Disease Institute, Children's Hospital Los Angeles, 4650 Sunset Blvd, Los Angeles, CA, 90027, US.
  • Bradfield SM; Cancer and Blood Disease Institute, Children's Hospital Los Angeles, 4650 Sunset Blvd, Los Angeles, CA, 90027, US.
  • Kyono W; Nemours Children's Health, 807 Children's Way, Jacksonville, FL, 32207, US.
  • Roth M; Kapi'olani Medical Center for Women & Children, 1319 Punahou Street, Honolulu, Hawai'i, 96826, US.
  • Klesges LM; Division of Pediatrics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, US.
  • Beauchemin M; Division of Public Health Sciences, Washington University School of Medicine, 600 So Taylor Ave, St. Louis, MO, 63110, US.
  • Grimes A; Columbia University School of Nursing/Herbert Irving Cancer Center, 560 West 168th Street, New York, NY, 10032, USA.
  • Tomlinson G; Pediatric Hematology Oncology, University of Texas Health, The Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, US.
  • Dupuis LL; Department of Medicine, Toronto General Hospital, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
  • Sung L; Program in Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, 686 Bay Street, Toronto, ON, M5G 0A4, Canada.
BMC Cancer ; 23(1): 350, 2023 Apr 17.
Article em En | MEDLINE | ID: mdl-37069510
BACKGROUND: There is substantial heterogeneity in symptom management provided to pediatric patients with cancer. The primary objective was to describe the adaptation process and specific adaptation decisions related to symptom management care pathways based on clinical practice guidelines. The secondary objective evaluated if institutional factors were associated with adaptation decisions. METHODS: Fourteen previously developed symptom management care pathway templates were reviewed by an institutional adaptation team composed of two clinicians at each of 10 institutions. They worked through each statement for all care pathway templates sequentially. The institutional adaptation team made the decision to adopt, adapt or reject each statement, resulting in institution-specific symptom management care pathway drafts. Institutional adaption teams distributed the 14 care pathway drafts to their respective teams; their feedback led to care pathway modifications. RESULTS: Initial care pathway adaptation decision making was completed over a median of 4.2 (interquartile range 2.0-5.3) weeks per institution. Across all institutions and among 1350 statements, 551 (40.8%) were adopted, 657 (48.7%) were adapted, 86 (6.4%) were rejected and 56 (4.1%) were no longer applicable because of a previous decision. Most commonly, the reason for rejection was not agreeing with the statement (70/86, 81.4%). Institutional-level factors were not significantly associated with statement rejection. CONCLUSIONS: Acceptability of the 14 care pathways was evident by most statements being adopted or adapted. The adaptation process was accomplished over a relatively short timeframe. Future work should focus on evaluation of care pathway compliance and determination of the impact of care pathway-consistent care on patient outcomes. TRIAL REGISTRATION: clinicaltrials.gov, NCT04614662. Registered 04/11/2020, https://clinicaltrials.gov/ct2/show/NCT04614662?term=NCT04614662&draw=2&rank=1 .
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Procedimentos Clínicos / Neoplasias Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Child / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Procedimentos Clínicos / Neoplasias Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Child / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article